Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The FDA gave full approval for Alzheimer's drug Leqembi in July. Despite the positive news, Biogen's stock didn't take off.

Why Isn't Biogen Stock Soaring After This Major FDA Approval?

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again

In recent weeks, three closely watched FDA decisions came in positive for the companies—followed by their stocks going negative.

FDA Approval Isn't Always a Happy Day for Biotech Investors

US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated with Alzheimer's disease. Developed by Japanese drug-maker Eisai and comarketed with Biogen Inc (NASDAQ:BIIB), the American pharmaceutical giant, the FDA's endorsement paves the way for Medicare and other insurance plans to cover the treatment for individuals with mild dementia and early symptoms of Alzheimer's disease.

Leqembi approval offers renewed hope for novel Alzheimer's disease treatments

Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.

Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug

Shares of Biogen Inc. BIIB, -3.48%, which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer's treatment Leqembi, “remain an under-owned turnaround story,” and the stock should benefit as sales gradually ramp up, Jefferies analysts wrote in a research note Sunday. The approval failed to give Biogen stock an immediate boost, as some analysts predicted a slow rollout for Leqembi and bottlenecks at infusion-therapy centers.

Biogen shares ‘an under-owned turnaround story,' Jefferies analysts say

Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.

FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides

Stocks often react differently from the way you think they might. That happened on July 7 as shares of Biogen Inc. NASDAQ: BIIB swooned 2.88% in heavy trading volume following news of full regulatory approval for its Alzheimer's treatment, Leqembi.

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

The FDA has granted full approval to Biogen and Eisai's anti-amyloid antibody drug Leqembi, but there is skepticism about its efficacy and safety. The approval led to a drop in Biogen's stock, in part due to the FDA's warning about potential side effects such as brain swelling and hemorrhaging. Leqembi's future may be impacted by competition from other Alzheimer's drugs, efficacy and safety concerns, and potential withdrawal of coverage by Medicare.

Biogen And Alzheimer's Disease: Too Early To Celebrate

The FDA just approved Biogen's new Alzheimer's treatment Leqembi. This could become the company's next billion-dollar product -- and kickstart growth.

Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?

Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.

Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know

Biogen Inc (NASDAQ: BIIB) is trading down this morning even though the Food and Drug Administration awarded full approval to its Alzheimer's drug – Leqembi.

FDA approves Biogen's Leqembi: the Alzheimer's drug will ‘surprise to the upside'

Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.

Sales of Alzheimer's drug Leqembi may be slow initially but could pick up in 2024

Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024.

Biogen's Alzheimer's Drug Rollout Could Be Slow

With U.S. approval of Eisai's and Biogen's Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.

More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

A milestone drug approval failed to boost Biogen Inc. BIIB, -2.65% shares early Friday, as analysts parsed the U.S. Food and Drug Administration's action Thursday on Alzheimer's treatment Leqembi.

Biogen's big Alzheimer's drug win fails to boost the stock as analysts see slow Leqembi rollout

Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Full approval likely means at least $100s millions/annual revenue since Medicare will reimbursement most of the patient cost for Leqembi. With the full approval, Leqembi sales should help BIIB's topline for years to come.

Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?

Biogen (NASDAQ: BIIB ) stock is in the news Friday after the company got approval from the FDA for its Alzheimer's drug. This covers the traditional approval of LEQEMBI.

BIIB Stock Alert: What to Know as FDA Approves Biogen's Alzheimer's Drug

Biogen Inc.'s stock BIIB, -0.31% rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company's Alzheimer's disease treatment co-developed with Eisai Co. Ltd. ESALF, +1.20%.

Biogen's stock slides premarket as analysts take mixed view of Alzheimer's disease drug approval

Eisai, a Japanese firm, and American drugs giant Biogen Inc (NASDAQ:BIIB) have received full Food & Drug Administration approval for Leqembi, a groundbreaking drug that curbs Alzheimer's disease progression. This approval represents a significant milestone as prior medications only addressed disease symptoms.

Alzheimer's drug, the first to slow disease progression, gets FDA green light

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer's disease

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Medicare enrollees can get the anti-amyloid treatment as a result of the agency's full approval.

FDA Approves Leqembi, Extending Alzheimer's Treatment to More Patients

The US Food and Drug Administration (FDA) has fully approved a drug that slows the progression of Alzheimer's disease for the first time.

First drug to slow progression of Alzheimer's disease approved in US

Leqembi costs $26,000 per year before insurance.

News for Biogen Stock (BIIB)